<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369965</url>
  </required_header>
  <id_info>
    <org_study_id>FB-ABWT-Ⅲ-301</org_study_id>
    <secondary_id>ChiCTR-TRC-14004276</secondary_id>
    <nct_id>NCT02369965</nct_id>
  </id_info>
  <brief_title>Test Albuvirtide in Experienced Patients</brief_title>
  <acronym>TALENT</acronym>
  <official_title>Efficacy and Safety of Albuvirtide Plus Lopinavir-ritonavir in HIV-1-infected Adults Failed Standard First-line ART Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frontier Biotechnologies Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frontier Biotechnologies Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of albuvirtide plus
      lopinavir-ritonavir in HIV-1-infected adults who failed first-line antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48-week, randomized, controlled, open-label, multicenter study of the safety and
      efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1 infected adults who are failing
      their first antiretroviral regimen and have HIV-1 RNA levels &gt;= 1000 copies/mL at screening.

      Subjects meeting inclusion criteria are randomized in a 1:1 ratio to receive either
      albuvirtide + lopinavir-ritonavir or lopinavir-ritonavir + TDF + 3TC. If TDF is used in the
      current regimen or genotypic resistance test shows primary mutation to TDF, zidovudine (AZT)
      or abacavir will be used. Albuvirtide will be given by weekly intravenous infusion and LPV/r
      will be given twice daily. The primary end point is the percentage of participants with HIV-1
      RNA&lt;50 copies/mL at Week 48, the secondary end points include the change of HIV-1 RNA from
      baseline through Week 48, the percentage of participants with HIV-1 RNA&lt;400 copies/mL at Week
      48, and the change of CD4 count from baseline through Week 48.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 50 copies/mL at Week 48</measure>
    <time_frame>week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline through Week 48 in HIV-1 RNA</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with HIV-1 RNA &lt; 400 copies/mL at Week 48</measure>
    <time_frame>week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline through Week 48 in CD4 count</measure>
    <time_frame>from baseline to 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albuvirtide</intervention_name>
    <description>albuvirtide 320mg administered intravenously once a week</description>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <other_name>ABT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir-ritonavir</intervention_name>
    <description>lopinavir-ritonavir 400/100mg administered orally twice daily</description>
    <arm_group_label>albuvirtide, lopinavir-ritonavir</arm_group_label>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>Kaletra</other_name>
    <other_name>LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>tenofovir 300mg administered orally once daily</description>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine</intervention_name>
    <description>lamivudine 300mg administered orally once daily</description>
    <arm_group_label>lopinavir-ritonavir,tenofovir,lamivudine</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 16 to 60 years old;

          2. Previously documented HIV infection on standard antibody-based test;

          3. Previous antiretroviral therapy (ART) with NRTIs/NNRTIs for more than 6 months;

          4. HIV RNA≥1000 copies/ml;

          5. In healthy condition by physical examination, biochemistry, hematology and urinalysis
             test,and electrocardiogram etc., without serious liver and renal damages;

          6. Fully understand the purpose, characteristics, procedures of the trial, and the
             potentially adverse events which might occur during study; willing and able to sign
             informed consent.

        Exclusion Criteria:

          1. Patients with acute HIV infection,or with AIDS-related disease, such as severe
             opportunistic infection or tumors;

          2. Previously received any protease inhibitors, HIV fusion inhibitors, HIV vaccines, or
             received other investigational drugs within 3 months;

          3. Co-treatment against hepatitis virus;

          4. Having abnormal values at screening as follows: Hemoglobin&lt;9g/dL, White blood count
             &lt;2×10^9/L, Neutrophil &lt;1×10^9/L, Platelet count &lt;75×10^9/L, Aminopherase &gt;3-fold upper
             limit of normal value, Total bilirubin &gt;2-fold upper limit of normal value, Creatinine
             &gt;upper limit of normal value, Creatine phosphokinase &gt;2-fold upper limit of normal
             value;

          5. With allergic constitution, or allergic history of the investigational drug and ART
             drugs;

          6. With serious chronic disease, metabolic disease (such as diabetes), mental disorder
             and nervous disease;

          7. Had a history of hemophilia A or B;

          8. Alcohol abuse or drug abuse;

          9. Pregnant women, breast feeding women, and women in child-bearing age disagreed with
             use of birth control;

         10. Unsuitable to participate in this study in the opinion of the site investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Xie</last_name>
    <role>Study Director</role>
    <affiliation>Frontier Biotechnologies Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheng Yao</last_name>
    <phone>+86 025 87158168</phone>
    <email>yaocheng@frontierbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Min Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongxing Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Hongxing Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital medical university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hao Wu</last_name>
    </contact>
    <investigator>
      <last_name>Hao Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Eighth People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiping Cai</last_name>
    </contact>
    <investigator>
      <last_name>Weiping Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Third People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Wang</last_name>
    </contact>
    <investigator>
      <last_name>Hui Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Infectious Disease Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingxia Zhao</last_name>
    </contact>
    <investigator>
      <last_name>Qingxia Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Changsha</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Wang</last_name>
    </contact>
    <investigator>
      <last_name>Min Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuhuang Zheng</last_name>
    </contact>
    <investigator>
      <last_name>Yuhuang Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalian Sixth People's Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhenxing Cui</last_name>
    </contact>
    <investigator>
      <last_name>Zhenxing Cui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhou Lu</last_name>
    </contact>
    <investigator>
      <last_name>Hongzhou Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tangdu Hospital of the Forth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongtao Sun</last_name>
    </contact>
    <investigator>
      <last_name>Yongtao Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifang Sheng</last_name>
    </contact>
    <investigator>
      <last_name>Jifang Sheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>AIDS</keyword>
  <keyword>Albuvirtide</keyword>
  <keyword>Treatment-experienced</keyword>
  <keyword>Fusion inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

